BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18480741)

  • 1. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
    Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
    Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
    Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours.
    Castaldi P; Rufini V; Treglia G; Bruno I; Perotti G; Stifano G; Barbaro B; Giordano A
    Radiol Med; 2008 Oct; 113(7):1056-67. PubMed ID: 18797822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms.
    Pfannenberg AC; Eschmann SM; Horger M; Lamberts R; Vonthein R; Claussen CD; Bares R
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):835-43. PubMed ID: 12682789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental value of
    Trogrlic M; Težak S
    Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
    Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors.
    Spanu A; Solinas ME; Farris A; Arru A; Chessa F; Madeddu G; Falchi A; Madeddu G
    Radiol Med; 2004; 107(1-2):113-27. PubMed ID: 15031703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
    Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I
    Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
    Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J
    Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
    Gómez M; Ferrando R; Vilar J; Hitateguy R; López B; Moreira E; Kapitán M; De Lima F; Agüero B; Gabriela Villegas M; Urdaneta N; Gutiérrez E; Battegazzore A; Bayardo K; Silveira A; Lago G; Páez A
    Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
    Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
    Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
    Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
    Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
    Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
    Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake?
    Ait Boudaoud A; Verges B; Petit JM; Tatulashvili S; Cochet A; Humbert O
    Nucl Med Commun; 2017 Sep; 38(9):737-743. PubMed ID: 28704340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
    Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
    Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
    Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
    Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.